Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantAV
ARCH Venture Partners
Activity from announced rounds
Activity in this selectionOct 18, 2026 · Jul 21, 2026
ARCH Venture Partners creates and backs companies built on scientific discoveries, with a healthcare focus on technologies that prevent, detect and treat disease.
The firm works through company formation as well as financing, using a network of partners to translate science into an operating business. It sizes capital to the development requirements, with investments ranging from very early commitments to hundreds of millions of dollars per company.
Its long-term model accommodates scientific programmes that need substantial development before commercial scale. Founders and researchers can engage around the creation of a company, rather than waiting until a conventional growth-stage investment case is established.
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $743M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionEncoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantMoonwalk Biosciences
Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.
$70MSeries B
ParticipantLifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosed